Florfenicol Microemulsion for Bovine Respiratory Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bovine and swine respiratory diseases pose significant economic losses due to high incidence of respiratory illness, mortality, and treatment costs, with existing antimicrobial therapies often requiring frequent administration and causing pulmonary damage and pyrexia, necessitating a more convenient and stable treatment solution.
Innovation Solution
A composition comprising florfenicol or similar antibiotics combined with unique carriers like triacetin and dimethylacetamide, administered subcutaneously to achieve sustained plasma concentrations and reduced injection site irritation, effectively treating bovine and swine respiratory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antimicrobial therapies are administered frequently to treat respiratory diseases, then treatment effectiveness is improved, but animal welfare deteriorates due to pulmonary damage and pyrexia
Solution Approach 1:
The patent changes the physical-chemical parameters of the antibiotic formulation by using microemulsion technology to create a stable, isotonic solution with optimized pH and osmolarity. This allows the antibiotic to be administered less frequently while maintaining therapeutic effectiveness, thereby reducing the harmful effects of repeated injections on animal welfare.
Solution Approach 2:
The patent introduces microemulsion carriers as intermediaries to deliver the antibiotic more effectively. These carriers improve the solubility, stability, and bioavailability of the antibiotic, enabling sustained release and reducing the frequency of administration needed to maintain effective treatment.
2Reliability
If antimicrobial drugs are administered at arrival to reduce respiratory illness incidence, then disease prevention is improved, but treatment complexity increases due to monitoring and isolation requirements
Solution Approach 1:
The patent creates a self-service system where the improved antibiotic formulation automatically provides sustained therapeutic levels through its microemulsion design. The formulation's inherent stability and controlled release properties eliminate the need for complex monitoring schedules and isolation protocols, as the treatment remains effective with simpler administration.
3Ease of manufacture
If conventional antibiotic formulations are used, then manufacturing simplicity is maintained, but product stability deteriorates requiring frequent administration
Solution Approach 1:
The patent uses composite materials by combining the antibiotic with specific microemulsion-forming substances that create a stable, isotonic solution. This composite formulation maintains physical-chemical stability and provides controlled release of the antibiotic, ensuring consistent plasma concentrations without complicating the manufacturing process.
Data Source
AI summary
Novel formulations containing a fluorinated chloramphenicol or thiamphenicol derivative antibiotic such as florfenicol, and methods for using such formulations in the treatment and prevention of infectious diseases of bovines and swine, including bovine respiratory disease.